 |
|
|
|
|
 |
Last Updated: Nov 1, 2009 - 11:48:48 PM |
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
Anti-angiogenics: a novel class of drugs against solid tumors
Researchers at the University of Minnesota have developed novel anti-cancer drugs to treat solid tumors. These "small molecules" belong to a class of pharmaceutical agents called anti-angiogenics. The new compounds are a refined form of drugs that effectively reduce blood flow to the tumor, thereby inhibiting tumor growth.
Jul 6, 2006 - 3:03:37 AM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab effective in treating chronic graft-versus-host disease
A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants.
Mar 24, 2006 - 7:14:37 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration Phase
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin(TM) Anti-Viral for the treatment of chronic hepatitis C virus infection (HCV).
Jan 18, 2006 - 6:00:37 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin effective in controlling Pancreatic Cancer
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced preclinical results showing that 3G4, the mouse equivalent of Tarvacin(TM) Anti-Cancer, was effective at controlling the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy when combined with the standard-of-care chemotherapy gemcitabine.
Jan 11, 2006 - 7:20:37 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab maintenance therapy dramatically improves survival in lymphoma
Two years of maintenance therapy with MabThera (rituximab) dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkins Lymphoma (NHL). The trial showed that the risk of death is halved for patients who receive MabThera maintenance therapy, compared to those who receive no maintenance treatment, irrespective of their initial therapy. We are conscious that these results open a new era in the management of indolent NHL, said William M. Burns, CEO of the Pharmaceuticals Division at Roche. Maintenance therapy with MabThera showed unprecedented survival benefits in a serious cancer disease which is currently considered incurable.
Dec 13, 2005 - 3:35:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Peregrine Pharmaceuticals Evaluating Therapeutic Opportunities for Tarvacin
Oct 25, 2005 - 5:10:38 AM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
Balancing Chk1 activity might produce less toxic cancer drugs
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs. The study is expected to help academic researchers and biotechnology and pharmaceutical companies design drugs that combat cancer using this checkpoint protein, but with fewer side effects.
Sep 4, 2005 - 8:32:38 AM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab to be Considered for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-positive, B-cell, non-Hodgkin's lymphoma
Genentech, Inc. , Biogen Idec, Inc. and Roche (SWX Zurich) today announced that the companies completed the filing of a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for an additional indication for Rituxan(R) (Rituximab), in previously untreated (front-line) patients with intermediate grade or aggressive, CD-20-positive, B-cell, non-Hodgkin's lymphoma (NHL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens.
Aug 18, 2005 - 11:44:38 AM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin(TM) starts with Phase I study against Hepatitis C Virus
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), announced today the initiation of a phase I anti-viral study of Tarvacin(TM), the Company's first Anti-Phospholipid Therapy candidate. The phase I study is an open-label, dose-escalation study in up to 32 adult patients with chronic hepatitis C virus (HCV) infection who either no longer respond to or failed standard therapy with pegylated interferon and ribavirin combination therapy.
Aug 8, 2005 - 5:39:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
New data support broad anti-viral potential of Tarvacin(TM)
The data presented at BIO 2005 showed that Tarvacin(TM) binds to enveloped virus particles representing 6 different virus families, binds to virally infected cells and inhibits viral replication in multiple virus systems. The data also indicated that Tarvacin(TM) provided significant protection against Cytomegalovirus (CMV) and Pichinde virus (an in vivo Lassa fever model) infections.
Jul 31, 2005 - 11:59:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin(TM) also useful in imaging solid tumors
Peregrine Pharmaceuticals, Inc reported that data was presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California showing the potential use of Tarvacin(TM), its lead Anti-Phospholipid Therapy agent, for imaging solid tumors.
Jul 31, 2005 - 11:12:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin(TM) to be evaluated for the treatment of Lassa fever
Peregrine Pharmaceuticals Inc. has announced that it has signed a Cooperative Research and Development Agreement (CRADA) for Material Transfer with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of Tarvacin(TM) to treat hemorrhagic diseases resulting from Ebola and Marburg viral infections.
Jul 31, 2005 - 11:01:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
DANCER Study shows RA drug rituximab is safe and well-tolerated
In the biggest study of its kind, researchers have shown that the drug rituximab, used to treat rheumatoid arthritis (RA) is safe and effective. The results were presented for the first time today (Thursday 9 June), at the Annual European Congress of Rheumatology, EULAR 2005, in Vienna.
Jun 9, 2005 - 1:25:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab may also benefit people with lupus
A drug used to treat cancer may also benefit people with lupus who have complications of the central nervous system. Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
Jun 9, 2005 - 1:25:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
PXD101: A Small Molecule HDAC Inhibitor for Advanced Solid Tumors
CuraGen Corporation (Nasdaq: CRGN - News) and TopoTarget A/S announced that preliminary Phase I data on PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of advanced solid tumors were presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.
May 17, 2005 - 8:42:38 AM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
FDA Permits Phase IIb Kidney Transplant Trial
Isotechnika Inc. announced today that the Company has received permission from the Food and Drug Administration of the United States to proceed with a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247.
May 13, 2005 - 5:44:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
TNFerade(TM) to be Studied for Locally Advanced Pancreatic Cancer Using Electronic Data Capture Solution
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that GenVec, Inc. (NASDAQ: GNVC) has selected Phase Forward's InForm(TM) electronic data capture (EDC) solution to manage a randomized, controlled Phase II clinical trial of its investigational oncology drug, TNFerade(TM).
May 10, 2005 - 8:39:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
Motexafin Gadolinium Works by Disrupting Key Metabolic Enzymes
The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.
May 1, 2005 - 8:57:38 PM
|
<< prev
next >>
|
|
|
|
